Epsilon Healthcare (ASX:EPN) is a diversified global healthcare and pharmaceuticals company with primary operations in Australia and Canada.
Epsilon Healthcare is the first ASX listed entity to fully own and operate end to end commercial medicinal cannabis production facilities under Australia’s cannabis regulations.
EPN owns a number of medicinal cannabis assets including the largest cannabis manufacturing facility in the Southern Hemisphere, the Tetra Health clinic, and the Medimar Platform – an end-to-end ecommerce solution for nutraceuticals and cannabis.
Epsilon Healthcare’s Southport Facility in Southport, Australia is one of the largest pharmaceutical GMP cannabis manufacturing facilities in the world.
EPN also owns and operates a fast-growing turnkey cultivation solutions provider, based in Vancouver, Canada.
This includes a hydroponics equipment and supplies wholesaler and retailer servicing the rapidly expanding cannabis sectors in North America and Europe.
Jarrod White, Chief Executive Officer
Mr. White is a Chartered Accountant and founding Director of Traverse Accountants Pty Ltd, a Corporate Advisory and Chartered Accounting Firm. In conjunction with his Corporate Advisory roles at Traverse Mr. White has been appointed Company Secretary and Chief Financial Officer of several other listed entities on the Australian Securities Exchange and has a sound knowledge of corporate governance and compliance. Jarrod has also been an advisor to a wide range of capital raisings, IPO’s and reverse takeover transactions and has a focus on working with growing companies in the exploration, technology and biotech space.
Sonny Didugu, Chief Operating Officer
Mr Didugu has significant corporate advisory, equity capital markets transactions, and listed entity compliance experience across a broad range of industry sectors including property development, gaming, fin-tech, esports, and cannabis. His past experience includes advisory roles within private equity houses, working within in-house counsel groups, and consulting to corporate advisory firms. Mr Didugu has previously acted for a wide range of listed and unlisted entities providing investor relations support, equity market transactions advice, and general corporate and governance advisory services. Mr Didugu holds a Bachelor of Laws (Honours) and is a Member of the Australian Institute of Company Directors.
Steven Xum Chairman (Non-Executive)
Steven Xu is the Managing Director of Une-Innovation Consulting Australia Pty Ltd and Founding Partner of INP Capital Inc which manages a series of venture capital funds. The venture capital funds invest in companies specialised in Medical/Healthcare, AI, Fintech and Industrial technology and Medical Cannabis across Australia, New Zealand, North America and Israel.
He has strong international connections and over 15 years’ experience working at PricewaterhouseCoopers and listed companies in Australia and China. He specialises in financing, IPO and M&A activities in a broad range of sectors. Steven completed a Bachelor of Management.
He is a member of the Institute of Chartered Accountants (Australia and New Zealand) and the Australian Institute of Company Directors.
Alan Beasley, Deputy Chairman (Non-Executive)
Alan Beasley has worked in the Investment Banking and Investment Management industries for over 30 years with Bankers Trust Australia, Goldman Sachs Asset Management, and BNP Paribas Asset Management Ltd. The last two positions as Managing Director and Australian Country Head. Alan is a director and former director of several listed and unlisted public and private companies including two public charities.
He has a passion for and experience in assisting to bring innovative and new technology companies to market, especially in the Health and Life Sciences sectors.
Alan is a Certified Practising Accountant, (CPA) Fellow of the Governance Institute of Australia, (FGIA) and Fellow of the Australian Institute of Company Directors. (FAICD).
He is currently Managing Director of Hudson Investment Group Ltd (ASX.HGL) and Non-Executive Chairman of AFT Corporation Limited (ASX.AFT).
Lou Cattelan, Non-Executive Director
Lou is a specialist in the pharmaceutical, nutraceutical, complementary healthcare, and allied health industry sectors with over 30 years’ experience across a broad range of operational and strategic areas including, quality assurance, supply chain management, new product development, TGA and FDA regulatory compliance, sales and marketing, business development, and special projects. Lou has sat on the Consumer Healthcare Products Australia (formerly ASMI, the peak industry body for the Australian Consumer Health Industry) Committee for Complementary Medicines as a key liaison between TGA and significant industry stakeholders.
Lou has now retired as Head of Sales and Marketing of Contract Pharmaceutical Services of Australia (CPSA). In this role over the past 19 years, he has consulted with all major Pharma companies including Pfizer, MSD, Mylan and GSK to take innovative concepts through to compliant finished products. He has also worked in senior hands-on positions with Ella Bache, Milpharma, Sunspot Products, Bayer Pharma and Blackmores.
Gary Radcliff, Non-Executive Director
Mr Radcliff is a practicing Barrister, having been first called to the Bar in 1984 and is the President of the Gold Coast Bar Association. Mr Radcliff is also a specialist adjudicator in relation to Dispute Resolution recognised by the Office of the Commissioner for Body Corporate and Community Management (Queensland, Australia).
Mr Radcliff provides a wealth of experience in corporate governance and compliance matters both in Australia and overseas. In addition to practicing law, Mr Radcliff has significant experience in project management, corporate advisory and company directorship in a wide range of sectors, most notably, pharmaceuticals, financial services and technology.